In situ analysis of N-linked Glycans as Potential Biomarkers of Clinical Course in Human Prostate Cancer

2021 ◽  
pp. molcanres.0967.2020
Author(s):  
Lindsey R Conroy ◽  
Alexandra E Stanback ◽  
Lyndsay E.A Young ◽  
Harrison A Clarke ◽  
Grant L Austin ◽  
...  
PROTEOMICS ◽  
2003 ◽  
Vol 3 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Jeremy C. Miller ◽  
Heping Zhou ◽  
Joshua Kwekel ◽  
Robert Cavallo ◽  
Jocelyn Burke ◽  
...  

2016 ◽  
Vol 22 (18) ◽  
pp. 4651-4663 ◽  
Author(s):  
Liana B. Guedes ◽  
Carlos L. Morais ◽  
Fawaz Almutairi ◽  
Michael C. Haffner ◽  
Qizhi Zheng ◽  
...  

2009 ◽  
Vol 8 (5) ◽  
pp. 1305-1311 ◽  
Author(s):  
Mounia Beloueche-Babari ◽  
Joanna C. Peak ◽  
L. Elizabeth Jackson ◽  
May-Yung Tiet ◽  
Martin O. Leach ◽  
...  

2005 ◽  
Vol 12 (1) ◽  
pp. 101-107 ◽  
Author(s):  
Yasuhiro Nakamura ◽  
Takashi Suzuki ◽  
Masao Nakabayashi ◽  
Mareyuki Endoh ◽  
Kazuhiro Sakamoto ◽  
...  

Androgens have been proposed to be actively produced in situ in human prostate cancer. These locally produced androgens have also been considered to play important roles in the pathogenesis and development of prostate cancer. Therefore, it is important to examine the status of this in situ androgen metabolism and/or synthesis in detail in order to improve the clinical response to hormonal therapy in patients diagnosed with prostate cancer. Several studies have previously demonstrated the expression of androgen-producing enzymes such as 5α-reductase types 1 and 2, and 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5), in human prostate carcinoma cells. However, their biological significance has remained largely unknown. In this study, we evaluated the immunoreactivities of these steroidogenic enzymes in human prostate cancer obtained from surgery (n=70), and correlated the findings with clinicopathological features of the patients. 17β-HSD5 immunoreactivity was detected in 54 cases (77%), 5α-reductase type 1 in 51 cases (73%) and 5α-reductase type 2 in 39 cases (56%). 5α-reductase type 2 immunoreactivity was significantly correlated with that of androgen receptor (AR), and 17β-HSD5 positive cases were significantly associated with clinical stage (TNM stage pT3 vs pT2). These data all suggest that androgen-producing enzymes, such as 5α-reductase type 1 and type 2, and 17β-HSD5 are expressed in a majority of prostate cancers, and are involved in the local production and actions of androgens in prostate cancers.


2007 ◽  
Vol 177 (4S) ◽  
pp. 210-211 ◽  
Author(s):  
Joshua M. Stern ◽  
Jennifer Stanfield ◽  
Jer-Tsang Hsieh ◽  
Jeffrey A. Cadeddu

2006 ◽  
Vol 175 (4S) ◽  
pp. 483-483
Author(s):  
Hitoshi Takayama ◽  
Norio Nonomura ◽  
Daizo Oka ◽  
Masahiro Shiba ◽  
Yasuyuki Arai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document